Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...

Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...

The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

England’s National Health Service will begin rolling out Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro over the next few months, though the medication will initially be made available to ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...